AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol
Damon P Eisen, Elizabeth M Moore, Karin Leder, Jessica Lockery, Emma S McBryde, John J McNeil, David Pilcher, Rory Wolfe, Robyn L Woods
BMJ Open | BMJ PUBLISHING GROUP | Published : 2017
INTRODUCTION: Sepsis is a leading global cause of morbidity and mortality, and is more common at the extremes of age. Moreover, the cost of in-hospital care for elderly patients with sepsis is significant. There are indications from experimental and observational studies that aspirin may reduce inflammation associated with infection. This paper describes the rationale and design of the AspiriN To Inhibit SEPSIS (ANTISEPSIS) trial, a substudy of ASPirin in Reducing Events in the Elderly (ASPREE). ANTISEPSIS primarily aims to determine whether low-dose aspirin reduces sepsis-related deaths in older people. Additionally, it will assess whether low-dose aspirin reduces sepsis-related hospitalisa..View full abstract
Awarded by National Health & Medical Research Council project
Awarded by NATIONAL INSTITUTE ON AGING
The ANTISEPSIS Study is funded by The National Health & Medical Research Council project grant number 1041986 (2013-2017).